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Abstract
Background—The Affordable Care Act (ACA) required most private insurance plans to cover 
contraceptive services without patient cost-sharing as of January 2013 for most plans. Whether the 
ACA’s mandate has impacted long-acting reversible contraceptives (LARC) use is unknown.
Objective—The aim of this article is to assess trends in LARC cost-sharing and uptake before 
and one year after implementation of the ACA’s contraceptive mandate.
Design—Retrospective cohort study using Truven Health MarketScan claims data from January 
2010–December 2013.
Subjects—Women aged 18–45 with continuous insurance coverage with claims for oral 
contraceptive pills, patches, rings, injections, or LARC during 2010–2013 (N=3,794,793).
Measures—Descriptive statistics were used to assess trends in LARC cost-sharing and uptake 
from 2010 through 2013. Interrupted time series models were used to assess the association of 
time, ACA, and time following the ACA on LARC cost-sharing and initiation rates, adjusting for 
patient and plan characteristics.
Results—The proportion of claims with $0 cost-sharing for IUDs and implants, respectively, 
rose from 36.6% and 9.3% in 2010, to 87.6% and 80.5% in 2013. The ACA was associated with a 
significant increase in these proportions and in their rate of increase (level and slope change both 
P<.001). LARC uptake increased over time with no significant change in level of LARC use post-
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ACA implementation in January 2013 (P=0.44) and a slightly slower rate of growth post-ACA 
than previously (beta coefficient for trend: −0.004, p<0.001).
Conclusions—The ACA has significantly decreased LARC cost-sharing, but during its first year 
had not yet increased LARC initiation rates.
Background
Almost half of pregnancies in the United States are unintended,1 leading to serious health 
consequences for women, children and communities2 and costing taxpayers an estimated 
$21 billion dollars a year.3 In recognition of this significant public health and economic 
issue, in 2011 the Institute of Medicine identified contraceptive care as a key preventive 
health service for women.4 The Department of Health and Human Services subsequently 
required that under the Affordable Care Act, non-grandfathered plans (i.e., those sold after 
March 2010 or older policies that have been modified since that time) cover the full range of 
FDA-approved contraceptive methods without patient cost-sharing beginning on or after 
August 1, 2012 or at the start of the next benefit year (January 2013 for most privately-
insured women).5, 6 Despite some variability across method types,6 evidence suggests that 
the ACA’s mandate overall translated into substantial reductions in cost-sharing for women 
in 2013.7, 8
Public health experts have hoped that eliminating contraceptive cost-sharing will promote 
increased and more effective use of prescription contraception, reducing unintended 
pregnancies.9 Particular interest has focused on long-acting reversible contraceptive (LARC) 
methods --intrauterine devices (IUDs) and implants—which are the most effective reversible 
methods available.10 Increased use of these methods in varying populations has been 
associated with lower rates of unplanned pregnancy.10–12 LARC methods have historically 
been associated with high initiation costs for many U.S. women13 and LARC has been 
underutilized in the U.S.,14 although rates of use have been steadily, albeit slowly, 
increasing.15, 16, 25 Several studies have led to optimism that reduced cost-sharing will 
further increase LARC use. For example, one study among mostly publicly insured women 
in St. Louis showed that eliminating cost-sharing for all contraceptive methods was 
associated with increased patient choice of LARC methods.17 An analysis of insurance 
claims demonstrated that lower levels of cost-sharing are associated with higher rates of 
LARC use among privately-insured women across the U.S.18
The early impact of the ACA’s contraceptive mandate on LARC use is not yet known. We 
sought to examine trends in LARC use following implementation of the ACA in 2013 using 
insurance claims data for a large cohort of women with private employer-sponsored 
insurance. We first examined changes in cost-sharing for LARC before and during 2013, the 
year following implementation of the ACA’s contraceptive mandate. We then examined 
monthly trends in LARC uptake and performed an interrupted time series analysis to 
identify whether implementation of the ACA’s contraceptive coverage mandate was 
associated with changes in prior levels of or trends in LARC use.
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Methods
We used the Truven Health MarketScan Commercial Claims and Encounters database from 
January 1, 2010 – December 31, 2013. The MarketScan database represents over 50 million 
non-retired employees and their dependents enrolled in commercial health insurance plan 
products sponsored by over 100 large or medium sized U.S.-based employers. The data 
include monthly enrollment, inpatient and outpatient medical claims, outpatient prescription 
drug claims, and reimbursed amounts paid by the health plan and patient for services billed. 
The study protocol was considered exempt by the Harvard Medical School Institutional 
Review Board.
Subjects and Contraceptive Claims
In our cohort, we included women aged 18–45 with prescription drug or medical coverage 
who had a prescription or medical claim for a contraceptive pill, ring, patch, depot 
medroxyprogesterone (DMPA) injection, or IUD or implant insertion during 2010–2013 and 
at least 12 months of continuous plan enrollment. We did not include claims for emergency 
contraception. Eligible women also had to have at least one contraceptive claim that fell 
after 6 months of continuous enrollment; this claim was identified as the “index” claim 
(N=3,638,644 women with prescription claims; N=501,024 with medical claims) although 
all of a woman’s contraceptive claims during the study period (before or after the “index” 
claim) were included in the analysis. From this cohort we excluded 150,540 women who 
filled more than one prescription claim for different short-acting products on the same day 
(although they could have multiple months’ supply of a method on a single claim), since we 
could not differentiate between administrative errors and multiple prescriptions. We also 
excluded 29,619 women for whom the sum of coinsurance and copayments were negative on 
any prescription or medical claim because we were concerned that these were errors. Some 
women had both a prescription and medical claim for an IUD, since these could represent a 
patient receiving the device from the pharmacy and subsequently having it placed by a 
provider, as required by some clinics. For these women, when the prescription and medical 
claims occurred within 42 days of each other (n=18,559 claims), we omitted the first claim; 
however, we excluded 9,692 prescription claims for IUDs and implants where there was no 
corresponding medical claim for insertion of the IUD or implant within 6 weeks. The final 
cohort included 3,794,793 unique patients and 40,593,279 contraceptive claims. Our cohort-
building process is illustrated in Figure 1.
Key variables
Cost sharing for LARC—To estimate cost-sharing, we added the copayment, co-
insurance, and deductible payments paid for a LARC prescription or procedure. We also 
performed a sensitivity analysis examining cost-sharing trends excluding deductibles. For 
IUDs and implants, we estimated out-of-pocket costs for a single IUD or implant placement; 
when a patient had both a prescription and medical claim for LARC within 42 days of each 
other, we totaled the cost-sharing for the prescription and medical claims (although only 
counted one of these claims for the purpose of assessing LARC rates). We did not include 
other costs associated with an office visit because non-contraceptive services might be 
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provided at the same time as contraception. Cost-sharing amounts are presented in 2013 
dollars after adjusting for inflation based on the medical price index.
LARC initiation—To identify rates of initiation of IUDs and implants among contraceptive 
users, for each month from 2010–2013 we identified the number of patients in our cohort 
with at least 1 medical or prescription claim for contraception in that month. If a patient had 
a claim for an IUD or implant, we counted that patient as an IUD or implant initiator in that 
month. If they had claims for only non-LARC methods (categorized as branded oral, generic 
oral, injection, patch, or ring) in that month, we considered the patient as a non-LARC user 
(but someone who was potentially eligible for LARC) in that month.
Independent variables—We measured time by month for cost-related and utilization 
trends. Because for most plans the ACA mandate took effect on January 1, 2013 we counted 
that month as the intervention month and time after that point was considered the post-
intervention period. We also conducted sensitivity analyses in which we counted April 2013 
as the intervention month because of the likelihood of delayed awareness of the benefit,19 as 
well as the possibility of delayed implementation by plans, since we noted that the 
proportion of LARC claims with $0 cost-sharing continued to increase throughout the first 
half of 2013..
Control variables—We documented each patient’s age group (18–25, 26–35, 36–45), 
geographic region, relationship of patient to the insured individual/employee (employee, 
spouse, dependent), and health plan type (comprehensive plan, exclusive provider 
organization or health maintenance organization, non-capitated or capitated/partially 
capitated point-of-service plan, preferred provider organization, consumer-driven health plan 
or high-deductible health plan, unknown).
Statistical analysis
Cost sharing—We described yearly trends in the proportion of contraceptive claims with 
$0 cost-sharing, and monthly trends in the proportion of LARC insertions that entailed $0 
cost-sharing from 2010–2013. We used segmented regression analysis of an interrupted time 
series to estimate the impact of the ACA on changes in the level and trend of rates of $0 
cost-sharing for LARC, adjusting for age, region, and plan type.2021 The key variables of 
interest were time (month, reflecting trends in $0 cost-sharing by month from January 2010 
– December 2013), ACA (reflecting a change in level of $0 cost-sharing after vs. before 
January 1, 2013), and time following the ACA (reflecting a change in the trend by month 
after the ACA - from January 2013 – December 2013). To account for repeated 
contraceptive claims for patients over time we used generalized estimating equations with a 
log link and Poisson distribution.22 We also conducted a sensitivity analysis in which we 
examined cost-sharing excluding deductibles.
LARC initiation—We estimated monthly rates of LARC initiation in our cohort of 
contraceptive users by calculating the proportion of women initiating an IUD or implant in a 
given month among women with claims for any contraceptive (long-acting and shorter-
acting methods) in that month. With the patient as the unit of analysis, we again used 
Pace et al. Page 4
Med Care. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
segmented regression analysis of an interrupted time series with generalized estimating 
equations and a log link/Poisson distribution to estimate the impact of the ACA on changes 
in the level and trend in LARC use beginning in January 2013 while accounting for the 
underlying time trend. We included the same covariates and key variables as the model 
predicting $0 cost-sharing. In addition, because we noted what appeared to be seasonal 
variation in LARC uptake (with drops in the first quarter of each year), we added dummy 
variables to adjust for quarter/season.23
Patients with short-acting contraceptive prescriptions providing more than one month’s 
supply who received a prescription during a previous month (or patients who received a 
DMPA injection, which lasts 3 months) would not be included in the denominator for a 
month in which they had drug on hand but did not have a claim. Thus, to assess the 
likelihood that this affected our findings, we conducted sensitivity analyses examining 
quarterly rather than monthly contraceptive trends. All analyses were conducted using SAS 
version 9.3 (SAS Institute, Carey NC).
Results
Cohort characteristics are shown in Table 1. Among contraceptive users, the proportion who 
were 18–25 years of age increased from 33.7% in 2010 to 41.5% in 2013. Similarly, the 
proportion of women who were dependents of the insured individual rose over time. There 
were some differences in distribution of plan types – most notably an increase in the 
proportion of women on consumer-driven and high-deductible health plans (7.4% in 2010 to 
13.9% in 2013). Consistent with the U.S. population,24 oral contraceptive pills were the 
most commonly used prescription contraceptive method among index claims, but the 
proportion of women using brand rather than generic pills declined over the four years. The 
proportion of total claims that were for LARC rose from 1% in 2010 to 1.6% in 2013. (Table 
1)
For all methods, the proportion of claims for which cost-sharing was $0, including LARC, 
rose substantially from 2010–2013. The proportion of patients paying $0 for IUDs and 
implants, respectively, was 36.6% and 9.3% in 2010, and 87.6% and 80.5% in 2013. (Table 
1) Figure 2 shows monthly trends in these proportions for IUDs and implants from 2010–
2013. At the start of 2010, 2011, and 2012, the proportion of LARC insertions with $0 cost-
sharing was lower compared with the end of the prior year and/or the following months of 
that year, suggestive of higher deductible payments at the start of those calendar years. 
Interrupted time series analysis (Table 2) demonstrated that the ACA (with January 1, 2013 
as the implementation date) was associated with a significant increase in the proportion of 
LARC claims with $0 cost-sharing (beta coefficient 0.65, p-value <0.001), as well as an 
increase in a monthly trend of rising proportions of claims with $0 cost-sharing (beta 
coefficient 0.004, p-value <0.001). We did identify the presence of autocorrelation in this 
model, likely due to the deductible patterns, however when we adjusted the model for 
autocorrelation, these findings did not significantly change. In our sensitivity analysis in 
which we excluded deductible payments from cost-sharing amounts, we did not observe the 
deductible-driven seasonal fluctuations in cost-sharing over the course of the calendar years 
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2010–2012; however the results of interrupted time series analysis were similar for the 
model including deductibles and in the model excluding them.
Figure 3 demonstrates the monthly proportions of women with contraceptive claims who 
had claims for LARC insertion. There was an overall rise in the monthly proportion of 
women initiating LARC from 2010 to 2013, with annual drops evident at the start of 2011 
and 2012, perhaps mirroring higher deductible payments. Interrupted time series analysis 
(Table 3), adjusting for patient characteristics and the quarter of the year of contraceptive 
initiation (to address seasonal trends in LARC use), confirmed a significant trend of rising 
LARC uptake by month over the study period (beta coefficient 0.02, p-value <0.001). 
Implementation of the ACA in January 2013, however, was associated with a small but 
statistically significant decrease in this monthly trend (beta coefficient −0.004, p-value < 
0.001). There was not a significant change in the level of LARC uptake after 2013. Among 
women with contraceptive claims in a given month, older women were more likely than 
women 18–25 to initiate LARC, and there were some differences in LARC initiation across 
regions and plan types. LARC initiation was lower in the first two quarters of each year 
compared with the last quarter. Results were similar when we used quarters as the unit of 
time. When we used April 1, 2013 as the date of ACA implementation, there was a 
significant increase in the level of LARC use associated with the ACA (beta coefficient 0.06, 
p-value <0.001, Table 3).
Discussion
Consistent with a recent study from a single large insurance carrier,8 our findings 
demonstrate that implementation of the ACA has had substantial impact on cost-sharing for 
LARC for women with employer-sponsored commercial insurance, in particular 
dramatically increasing the proportion of women with $0 cost-sharing for LARC insertions. 
In interrupted time series analyses adjusting for patient and plan characteristics, rates of 
LARC use in our population rose steadily from 2010–2013, consistent with findings from a 
national survey that has shown steady increases from 2009–2012.25 Immediately after 
implementation of the ACA’s mandate for most plans in January 2013, the proportion of 
commercially insured contraceptive users initiating LARC methods was not higher than 
what prior trends would predict. However, our sensitivity analysis suggests that by April 
2013, there may have been increases in LARC uptake beyond those predicted by previous 
trends. Despite this possible increase in level of LARC use, the previous rate of rise in 
LARC rates from 2010–2012 appeared to slow slightly in 2013.
Overall, our findings suggest that although reduced cost-sharing associated with the ACA’s 
mandate did not have an immediate effect on LARC use, it may be associated with increases 
in LARC uptake beyond the increases that would be predicted by previous trends as early as 
April 2013. This finding lends cautious support to studies demonstrating that reduced cost-
sharing is associated with higher rates of LARC use.18, 26 The delay in increased uptake 
between January and April 2013 suggested by our sensitivity analysis may have occurred 
because of a lag in cost-sharing decreases, since cost-sharing continued to decline 
throughout 2013, perhaps because of some plans’ delayed implementation of the rule. The 
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delay might also result from low initial awareness of or confusion about the benefit 
changes.19
We had expected to see an increase in the previously rising trend of LARC uptake rates 
following the ACA mandate. The reason for the slight flattening of the trend in 2013 is not 
clear. Ongoing analysis in subsequent years will be imperative to understand the longer-term 
impact of the ACA on levels and trends in LARC use. Reductions in cost-sharing alone may 
not ultimately be sufficient to make LARC available to all women desiring or needing it. 
LARC remains unavailable on-site at many outpatient clinics,2728 because of insufficient 
numbers of providers trained,29, 30 and administrative and financial barriers for facilities. 
LARC clinical protocols (for example, those requiring multiple visits for counseling and 
placement31) may pose additional barriers to patient access. Successful projects such as the 
CHOICE project in St. Louis,26 an intervention to promote LARC use at Kaiser Permanente 
in California,32 and a Colorado state-wide initiative to promote LARC use among low-
income teens,12 incorporated provider training, improved patient counseling, and (in 
Colorado’s case) reductions in the up-front cost of devices to clinics, in addition to reduced 
patient cost-sharing. Further, even when barriers to LARC are reduced, many patients may 
still choose short-acting methods, whether because of misperceptions associated with LARC 
methods33 or because of informed choice. It is possible that the ACA’s decrease in cost 
sharing for other methods of contraception make those methods relatively more appealing to 
women who may have considered initiating LARC.
This analysis has several strengths. We used a large dataset of claims from multiple insurers, 
increasing the generalizability of our findings. Our use of claims data allows assessment of 
actual contraceptive use rather than relying on self-report as has been done in other studies 
of LARC rates.25 Further, use of an interrupted time series analysis allows assessment of 
whether the ACA’s contraceptive coverage mandate impacted LARC use controlling for pre-
existing trends.
Our analysis has several limitations, however. First, we were only able to include procedures 
and contraceptive methods that are reimbursed by a patient’s insurance; methods that were 
utilized but not covered at all, or obtained outside of a patient’s insurance plan, are not 
represented in the data. Similarly, we could only examine costs for methods that were 
actually utilized. This could lead to underestimation of average cost-sharing for a given 
method (including LARC) if among certain plans that method was infrequently selected 
because it was prohibitively expensive. Second, we have limited information on individual 
patient characteristics and about the health plan’s benefit design, reducing our ability to 
assess for confounders as well as other factors that might significantly impact cost-sharing 
and LARC use. This also limits our ability to determine the generalizability of our sample to 
the larger population of women with employer-sponsored insurance, and to analyze 
differential effects of the ACA on different sub-groups. Third, our estimation of 
contraceptive rates has some limitations. Since we used monthly contraceptive claims rather 
than individual women using contraception as the denominator, our LARC rates should not 
be compared with national estimates of LARC usage.25 In addition, because of our study’s 
eligibility criteria, women who had a LARC method placed during her first 6 months of plan 
enrollment would not be included in the numerator. However, we would not expect these 
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factors to impact our assessment of trends. The final and most important limitation to our 
study is that our analysis represents contraceptive choice in a very early period following the 
ACA, when patients and providers may not yet be fully aware of and utilizing the 
contraceptive benefit.19
In conclusion, this study demonstrates that the ACA has had substantial impact on cost-
sharing for LARC among women with employer-sponsored insurance. Although LARC 
uptake did not appear to increase immediately in 2013, findings of our sensitivity analysis 
suggest that as of April 2013, the proportion of women initiating LARC rose beyond the 
level that would be predicted by previous trends. Ongoing assessment will be important to 
examine the impact of the policy change on contraceptive choice as women’s and providers’ 
awareness rises and as efforts to address other barriers to LARC use grow.
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Figure 1. 
Study cohort building process
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Figure 2. 
Percent of LARC claims with $0 cost-sharing by month, 2010–2013
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Figure 3. 
Monthly rates of LARC initiation among women with contraceptive claims, 2010–2013
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Table 1
Characteristics of contraceptive users and claims by year
Patient and plan characteristics 2010 2011 2012 2013
Patient characteristics*
Mean age in years (SD) 30.2 (7.5) 29.6 (7.4) 29.2 (7.4) 28.9 (7.5)
Age groups, N (%)
 18–25 years 491,114 (33.7) 715,583 (37.3) 794,570 (39.5) 681,603 (41.5)
 26–35 years 572,156 (39.3) 743,736 (38.7) 763,625 (38.0) 595,321 (36.3)
 36–45 years 393,201 (27.0) 460,505 (24.0) 453,369 (22.5) 364,718 (22.2)
Region, N (%)
 Northeast 221,605 (15.2) 332,637 (17.3) 369,269 (18.4) 306,070 (18.6)
 Midwest 382,639 (26.3) 470,737 (24.5) 491,813 (24.5) 369,927 (22.5)
 South 575,189 (39.5) 732,673 (38.2) 734,789 (36.5) 570,918 (34.8)
 West 272,358 (18.7) 335,105 (25.2) 374,894 (28.2) 346,734 (21.1)
 Unknown 4,680 (0.32) 48,672 (2.5) 40,799 (2.0) 47,993 (2.9)
Relationship of patient to employer, N (%)
 Employee 732,242 (50.3) 938,418 (48.9) 954,256 (47.4) 749,069 (45.6)
 Spouse 296,186 (20.3) 367,770 (19.2) 380,568 (18.9) 302,987 (18.5)
 Dependent 428,043 (29.4) 613,636 (32.0) 676,740 (29.3) 589,586 (35.9)
Health plan types, N (%)
Comprehensive 14,803 (1.0) 15,414 (0.8) 16,885 (0.8) 16,299 (1.0)
Exclusive provider organization and health maintenance 
organization
282,841 (19.4) 334,459 (17.4) 291,567 (14.5) 267,670 (16.3)
Point-of-service 113,557 (7.8) 144,256 (7.5) 142,920 (7.1) 134,357 (8.2)
Preferred-provider organization 905,479 (62.2) 1,168,956 (60.9) 1,266,136 (62.9) 972,178 (59.2)
Consumer-driven and high-deductible health plans 107,110 (7.4) 147,800 (7.7) 170,680 (8.5) 227,626 (13.9)
Missing 32,681 (2.2) 108,939 (5.7) 123,376 (6.1) 23,512 (1.4)
Contraceptive types per claim, N (%)**
Branded Oral 2,136,905 (24.8) 2,401,637 (21.8) 2,281,642 (19.9) 1,640,624 (17.3)
Generic Oral 5,650,271 (65.6) 7,596,218 (68.8) 8,088,701 (70.6) 6,923,986 (73.0)
Injection 76,693 (0.9) 107,583 (1.0) 117,291 (1.0) 117,281 (1.2)
Patch 113,094 (1.3) 121,819 (1.1) 107,759 (0.9) 89,614 (0.9)
Ring 546,419 (6.4) 684,323 (6.2) 693,499 (6.1) 561,134 (5.9)
IUD 78,406 (0.9) 117,614 (1.1) 142,717 (1.3) 136,333 (1.4)
Implant 7,414 (0.1) 13,548 (0.1) 18,494 (0.2) 22,260 (0.2)
Rates of $0 cost-sharing for different contraceptive types 
N(%)**
Branded Oral 189,428 (8.9) 165,837 (6.9) 220,522 (9.7) 880,385 (53.7)
Generic Oral 523,590 (9.3) 587,305 (7.7) 1,004,033 (12.4) 5,562,270 (80.3)
Injection 7,390 (9.6) 8,839 (8.2) 13,940 (11.9) 88,215 (75.2)
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Patient and plan characteristics 2010 2011 2012 2013
Patch 9,763 (8.6) 8,250 (6.8) 11,790 (10.9) 58,926 (65.8)
Ring 47,498 (8.7) 49,655 (7.3) 78,826 (11.4) 369,619 (65.9)
IUD 28,724 (36.6) 44,002 (37.4) 57,406 (40.2) 119,423 (87.6)
Implant 2,308 (9.3) 4,263 (31.1) 6,283 (34.0) 17,914 (80.5)
*
Distribution of patient and contraceptive characteristics at the time of the first contraceptive claim per year for each patient. A patient’s 
characteristics could be represented in multiple years if she had claims in multiple years.
**Among all contraceptive claims
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Table 2
Interrupted time series analysis of $0 cost-sharing among LARC users, 2010–2013
Characteristic Beta coefficient P-value
Intercept −1.07 <0.001
Overall change in trend by month 0.007 <0.001
After ACA change in level 0.65 <0.001
After ACA change in trend by month 0.004 <0.001
Age group
 18–25 years Reference
 26–35 years 0.03 <0.001
 36–45 years 0.01 0.004
Region
 Northeast Reference
 Midwest −0.12 <0.001
 South −0.28 <0.001
 West −0.07 <0.001
 Unknown −0.21 <0.001
Health plan type
Comprehensive 0.08 <0.001
Exclusive provider organization and health maintenance organization 0.26 <0.001
Point-of-Service 0.21 <0.001
Preferred-provider organization Reference
Consumer-driven and high-deductible health plans 0.10 <0.001
Missing 0.27 <0.001
ACA=Affordable Care Act
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Table 3
Interrupted time series analysis of monthly rates of LARC initiation among women with contraceptive claims, 
2010–2013
January 2013 as intervention point April 2013 as intervention point*
Characteristic Beta coefficient p-value Beta coefficient p-value
Intercept −4.78 <0.001 −6.17 <0.001
Overall change in trend by month 0.02 <0.001 0.02 <0.001
After ACA change in level −0.004 0.58 0.06 <0.001
After ACA change in trend by month −0.004 <0.001 −0.02 <0.001
Age group
 18–25 years Reference
 26–35 years 0.60 <0.001 0.60 <0.001
 36–45 years 0.70 <0.001 0.70 <0.001
Region
 Northeast Reference
 Midwest 0.09 <0.001 0.09 <0.001
 South 0.18 <0.001 0.18 <0.001
 West 0.37 <0.001 0.37 <0.001
 Unknown 0.23 <0.001 0.23 <0.001
Health plan type
Comprehensive −0.12 <0.001 −0.12 <0.001
Exclusive provider organization and health maintenance 
organization
0.06 <0.001 0.06 <0.001
Point-of-Service −0.03 <0.001 −0.03 <0.001
Preferred-provider organization Reference Reference
Consumer-driven and high-deductible health plans −0.12 <0.001 −0.13 <0.001
Missing −0.23 0.001 −0.23 <0.001
Quarter of year
Quarter 1 −0.24 <0.001 −0.25 <0.001
Quarter 2 −0.17 <0.001 −0.19 <0.001
Quarter 3 −0.006 0.09 −0.02 <0.001
Quarter 4 Reference
ACA=Affordable Care Act
*Sensitivity analysis performed to address possible delayed adoption of the ACA contraceptive mandate
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